One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
Abstract Objectives To explore the frequency and predictors of flares over 2 years during a treat-to-target strategy with urate-lowering therapy (ULT) in patients with gout. Methods In the treat-to-target, tight control NOR-Gout study patients started ULT with escalating doses of allopurinol. Flares...
Main Authors: | Till Uhlig, Lars F. Karoliussen, Joe Sexton, Tore K. Kvien, Espen A. Haavardsholm, Fernando Perez-Ruiz, Hilde Berner Hammer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-04-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-022-02772-3 |
Similar Items
-
The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
by: Pang L, et al.
Published: (2023-09-01) -
Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
by: Tore K Kvien, et al.
Published: (2023-11-01) -
Risk Factors for Postsurgical Gout Flares after Thoracolumbar Spine Surgeries
by: Kuan-Jung Chen, et al.
Published: (2022-06-01) -
Egyptian consensus on treat-to-target approach of gout: evidence-based clinical practice guidelines for the management of gout
by: Yasser El Miedany, et al.
Published: (2022-05-01) -
Gout, flares, and allopurinol use: a population-based study
by: Charlotte Proudman, et al.
Published: (2019-05-01)